Author:
Yoshihara Fumiki,Matsuzawa Yasushi,Nakatsuka Kiyomasa,Kirigaya Jin,Takeuchi Ichiro,Kimura Kazuo,Konishi Masaaki,Tamura Kouichi,Fukui Kazuki,Tsukahara Kengo,Shimizu Hiroyuki,Iwabuchi Keisuke,Yamada Yu,Saka Kenichiro,Sato Yukihito,Ogawa Masahiro,Hayakawa Kayoko,Ohmagari Norio,Ikeda Syuhei,Akao Masaharu,Shimomura Hideki,Kihara Yasuki,Yoshimoto Akihiro,Morita Masanori,Kumada Norihiko,Ogata Soshiro,Nishimura Kunihiro,Arisato Tetsuya,Matsuo Miki,Kishida Masatsugu,Yasuda Satoshi,Ogawa Hisao
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Pranata R, Permana H, Huang I, Lim MA, Soetedjo NNM, Supriyadi R, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14:983–90.
2. Caldeira D, Alves M, Gouveia E Melo R, Silvério António P, Cunha N, Nunes-Ferreira A, et al. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;31:100627.
3. Alamer AA, Almulhim AS, Alrashed AA, Abraham I. Mortality, severity, and hospital admission among COVID-19 patients with ACEI/ARB Use: A meta-analysis stratifying countries based on response to the first wave of the pandemic. Healthcare. 2021;9:127.
4. Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou MS, Doumas M. Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. evidence for significant geographical disparities. Curr Hypertens Rep. 2020;22:90.
5. Yoshihara F, Ohtsu H, Nakai M, Tsuzuki S, Hayakawa K, Terada M, et al. Renin-angiotensin system blocker and the COVID-19 aggravation in patients with hypertension, diabetes, renal failure, Cerebro-cardiovascular disease, or pulmonary disease: Report by the COVID-19 Registry Japan. J Cardiol. 2022;80:292–97.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献